Form D · Pharmaceuticals
Aarvik Therapeutics, Inc.
Hayward, CA · CIK 0001881431
Offering snapshot reported Dec 11, 2024 · SEC filing
- Reported sold
- $1.17M Offering amount: $15M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 11, 2024 | Initial | $1,165,000 | No comparison | 5 | SEC filing |
| Sep 2, 2021 | Initial | $8,333,333 | No comparison | 112 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-531747
Source: Form D, filed Dec 11, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anula Jayasuriya | Director |
| Jagath Reddy Junutula | Director, Executive |
| Ram Kalakoti Reddy | Director |
| Richard Scheller | Director |
| Sachdev Sidhu | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
31363 Medallion Drive
Hayward, CA, 94544
Hayward, CA, 94544